How did Danaher's Biotechnology segment fare in 2024?

Danaher's Biotechnology segment experienced a slight decline of 0.5% in revenue in 2024, according to the company's Q3 2024 earnings report. This decline was part of a broader trend affecting the segment, as noted in the second-quarter 2024 earnings report, where core sales in the Biotechnology segment dropped 9% year over year. The segment's performance was impacted by factors such as slowing growth in China and a funding crunch in biotech, which weighed on demand for contract research services. Despite these challenges, the Biotechnology segment's operating profit was reported at $462 million for Q3 2024, representing a 3.8% year-over-year decline.